Pyxis Oncology Revenue and Competitors

Boston, MA USA

Location

$174M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Pyxis Oncology's estimated annual revenue is currently $11.7M per year.(i)
  • Pyxis Oncology's estimated revenue per employee is $147,570
  • Pyxis Oncology's total funding is $174M.
  • Pyxis Oncology's current valuation is $337.5M. (January 2022)

Employee Data

  • Pyxis Oncology has 79 Employees.(i)
  • Pyxis Oncology grew their employee count by -7% last year.

Pyxis Oncology's People

NameTitleEmail/Phone
1
Chief Medical OfficerReveal Email/Phone
2
Chief Staff, MedicalReveal Email/Phone
3
VP, Facilities & Business OperationsReveal Email/Phone
4
Head Analytical Development and QCReveal Email/Phone
5
SVP, Head Global Regulatory AffairsReveal Email/Phone
6
VP, R&D QualityReveal Email/Phone
7
VP, Investor RelationsReveal Email/Phone
8
VP, Head DiscoveryReveal Email/Phone
9
SVP, Portfolio and Project ManagementReveal Email/Phone
10
SVP Head Non-Clinical ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Pyxis Oncology?

Pyxis Oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor micro-environment.

keywords:N/A

$174M

Total Funding

79

Number of Employees

$11.7M

Revenue (est)

-7%

Employee Growth %

$337.5M

Valuation

N/A

Accelerator

Pyxis Oncology News

2022-04-17 - Pyxis Oncology, Inc. (NASDAQ:PYXS) Director Mark Chin ...

Get Pyxis Oncology alerts: Large investors have recently bought and sold shares of the company. Citigroup Inc. bought a new position in shares...

2022-04-06 - Pyxis Oncology Announces Leadership Changes

Pyxis Oncology Announces Leadership Changes. Published: Apr 13, 2022. Ronald Herbst, Ph.D., stepping down as Chief Scientific Officer; Jan Pinkas, Ph.D.,...

2022-03-30 - Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 ...

Pyxis Oncology, Inc. is a multi-asset, multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By...

2021-03-30 - After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B

It’s been a nice month for Pyxis Oncology: After penning a major licensing deal with Pfizer, the startup now has $152 million extra in the bank to help it push on with its expanded pipeline. This also built on the ADC licensed from LegoChem Biosciences late last year, now known as PYX-202, for ...

2021-03-30 - ARIX BIOSCIENCE PLC Arix leads USD152 million Series B financing for Pyxis Oncology

Arix Bioscience PLC (ARIX) Arix leads USD152 million Series B financing for Pyxis Oncology 30-March-2021 / 13:01 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =--------------------------------- ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.3M7911%N/A
#2
$11.9M79-1%N/A
#3
$21.3M797%N/A
#4
$18M7932%N/A
#5
$17.4M797%N/A